Opinion: The industry that cries wolf: pharma and innovation
Drug companies play games. One of them involves product hopping — switching from one version of a drug to a trivially different version just to keep generic rivals off the market.
Congress is actively considering legislation targeting this conduct. In June, the Senate Judiciary Committee passed by a 22-0 vote the Affordable Prescriptions for Patients Act of 2019. Rep. David Cicilline (D-R.I.) recently introduced companion legislation, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2019. Both aim to quash anticompetitive behaviors by drug companies, and take specific aim at product hopping.
Read Original Article: Opinion: The industry that cries wolf: pharma and innovation »
